Which analyst expects The Oncology Institute Inc. (TOI) to perform well in the near future?

As of close of business last night, The Oncology Institute Inc.’s stock clocked out at $1.53, down -8.38% from its previous closing price of $1.67. In other words, the price has decreased by -$0.1400 from its previous closing price. On the day, 363232 shares were traded. TOI stock price reached its highest trading level at $1.6000 during the session, while it also had its lowest trading level at $1.5000.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report



To gain a deeper understanding of TOI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.10 and its Current Ratio is at 4.40. In the meantime, Its Debt-to-Equity ratio is 0.62 whereas as Long-Term Debt/Eq ratio is at 0.62.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on September 14, 2022, initiated with a Buy rating and assigned the stock a target price of $7.

On August 15, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $10.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 14 when Kaushal Mohit sold 15,994 shares for $2.13 per share. The transaction valued at 34,083 led to the insider holds 25,534 shares of the business.

Havencrest Healthcare Partners sold 365,321 shares of TOI for $851,198 on Nov 11. The 10% Owner now owns 13,362,873 shares after completing the transaction at $2.33 per share. On Nov 10, another insider, Havencrest Healthcare Partners, who serves as the 10% Owner of the company, sold 61,281 shares for $2.98 each. As a result, the insider received 182,617 and left with 13,728,194 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.50 while its Price-to-Book (P/B) ratio in mrq is 0.86.

Stock Price History:

Over the past 52 weeks, TOI has reached a high of $12.66, while it has fallen to a 52-week low of $1.48. The 50-Day Moving Average of the stock is 4.0618, while the 200-Day Moving Average is calculated to be 6.0116.

Shares Statistics:

It appears that TOI traded 163.48K shares on average per day over the past three months and 257.56k shares per day over the past ten days. A total of 72.18M shares are outstanding, with a floating share count of 55.78M. Insiders hold about 0.40% of the company’s shares, while institutions hold 74.90% stake in the company. Shares short for TOI as of Oct 13, 2022 were 1.06M with a Short Ratio of 0.97M, compared to 886.13k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 1.44% and a Short% of Float of 6.16%.

Earnings Estimates

As of right now, 2 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.15 and low estimates of -$0.19.

Analysts are recommending an EPS of between -$0.2 and -$0.51 for the fiscal current year, implying an average EPS of -$0.35. EPS for the following year is -$0.35, with 2 analysts recommending between -$0.05 and -$0.65.

Revenue Estimates

Based on 2 analysts’ estimates, the company’s revenue will be $343.3M in the next fiscal year. The high estimate is $350.6M and the low estimate is $336M. The average revenue growth estimate for next year is up 27.00% from the average revenue estimate for this year.